Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-01-23

Clinical Trial Update: A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria [Phase 2]

View source ↗

Summary

Phase 2 trial assessing AK002 for antihistamine-resistant chronic urticaria has completed with posted results in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AK002 (AK002)

Snippet

Sponsor: Allakos Inc. | Conditions: Chronic Urticaria | Phase 2 | Status: COMPLETED | Results posted: 2024-01-23